Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine ...

The Food and Drug Administration is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children under 5 years old, a move that would add another barrier for parents ...

The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy ...

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Pfizer, Inc. (PFE) stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance.